Philogen SpA (MIL:PHIL) Research & Development: €3.4 Mil (TTM As of Dec. 2025)


MIL:PHIL Philogen SpA MIL:PHIL
62 GF Score
Price €23.30
GF Value €227.22
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Philogen SpA Research & Development?

Philogen SpA MIL:PHIL +2.19% 62 Research & Development is €3.4 Mil as of Dec. 2025. GuruFocus rates MIL:PHIL with a GF Score™ of 62/100 and a GF Value™ of €227.22 (Possible Value Trap). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Philogen SpA's Research & Development for the six months ended in Dec. 2025 was €2.1 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €3.4 Mil.

Philogen SpA  (MIL:PHIL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Philogen SpA Research & Development Related Terms

Philogen SpA Research & Development Historical Data

* Premium members only.

The historical data trend for Philogen SpA's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Philogen SpA Research & Development Chart

Philogen SpA Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 0.91 1.94 3.50 2.19 3.42

Philogen SpA Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.66 0.83 1.37 1.32 2.10
MIL:PHIL
62GF Score
Philogen SpA MIL:PHIL
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Philogen SpA Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €3.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €3.4 Mil mean?
Philogen SpA (MIL:PHIL) has a Research & Development of €3.4 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Philogen SpA and its competitors.
Is Philogen SpA's Research & Development too high?
Philogen SpA's current Research & Development is €3.4 Mil. Overall, Philogen SpA has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Philogen SpA's Research & Development compare to VRTX and REGN?
Philogen SpA's Research & Development of €3.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Philogen SpA and its competitors. Philogen SpA's current Research & Development is €3.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Philogen SpA stock overvalued right now?
Based on GuruFocus' analysis, Philogen SpA (MIL:PHIL) is currently considered Possible Value Trap. The stock's GF Value™ is €227.22, compared to a current price of €23.30 — trading 89.7% below its estimated fair value. The current Research & Development is €3.4 Mil. Philogen SpA's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Philogen SpA (MIL:PHIL), the current Research & Development is €3.4 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Philogen SpA (MIL:PHIL) Overvalued in 2026?

Based on GuruFocus' analysis, Philogen SpA stock appears to be undervalued. The current stock price of €23.30 is trading 89.7% below its estimated GF Value™ of €227.22. GuruFocus considers Philogen SpA to be Possible Value Trap.

Key valuation signals for MIL:PHIL:

  • Research & Development: €3.4 Mil
  • GF Value™: €227.22 vs. price of €23.30 (89.7% below fair value)
  • GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the MIL:PHIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Philogen SpA Business Description

Other Exchanges 78Q:Germany
Address Piazza La Lizza No. 7, Siena, ITA, 53100
Philogen SpA is a biotechnology company engaged in the research and development of antibody-based therapeutics for the treatment of cancer and chronic inflammatory diseases. The company's pipeline includes products such as Nidlegy, Fibromun, Darleukin, and Dekavil, targeting oncology and other serious conditions. Geographically, the company operates in the European Union, Switzerland, and the United States of America.
62GF Score

Get the complete analysis for MIL:PHIL

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€23.30
Price
€227.22
GF Value